Abstract
Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Current Drug Targets
Title: Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Volume: 2 Issue: 3
Author(s): Gene C. Palmer
Affiliation:
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Abstract: Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Export Options
About this article
Cite this article as:
Palmer C. Gene, Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348335
DOI https://dx.doi.org/10.2174/1389450013348335 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of AMPA and Kainate Receptors
Current Medicinal Chemistry MicroRNA 155, Factor XIII and Type 2 Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Curcumin and its Derivatives: Their Application in Neuropharmacology and Neuroscience in the 21st Century
Current Neuropharmacology Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science Cerebellar Hemangioblastomas in a High-risk Pregnancy: A Case Report and Review of Literature
Current Medical Imaging Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis
Current Drug Targets Bifrontal ECT: A Systematic Review and Meta-Analysis of Efficacy and Cognitive Impact
Current Psychiatry Reviews The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Prediction of Ion Channels and their Types from Protein Sequences: Comprehensive Review and Comparative Assessment
Current Drug Targets Editorial [Hot Topic: GABA and Glutamate as Targets in Medicinal Chemistry (Guest Editor: Dr. Julianna Kardos)]
Current Topics in Medicinal Chemistry An Insight into Diverse Activities and Targets of Flavonoids
Current Drug Targets Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Introduction: P2 Receptors
Current Topics in Medicinal Chemistry The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: The Activity of Products From Cnidaria: A Therapeutic Tool in Neurological Diseases? Part II)
Central Nervous System Agents in Medicinal Chemistry Multicomponent Reactions Applied to Total Synthesis of Biologically Active Molecules: A Short Review
Current Topics in Medicinal Chemistry Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design